Overview

This trial is active, not recruiting.

Condition neuroendocrine tumors
Sponsor University Medical Center Groningen
Start date July 2015
End date October 2016
Trial size 60 participants
Trial identifier NCT02507908, 201500365

Summary

The objective of this observational laboratory study is to measure the correlation between 5-hydroxyindolacetic acid (5-HIAA) in platelet rich plasma and 5-HIAA in 24-hours urine collection in adult patients with a serotonin-producing neuro-endocrine tumor. Plasma and urine of included patients are collected and 5-HIAA values are measured with LCMS-MS and analysed.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Time perspective prospective

Primary Outcomes

Measure
the correlation between 5-HIAA in PRP and 5-HIAA in 24-hour urine collection
time frame: 4 days

Secondary Outcomes

Measure
the course of the disease according to the course of 5-HIAA in plasma
time frame: 1 year

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: - Serotonin in platelets > 5.4 nmol / 10^9 and 5-HIAA in 24-hours urine >3.8 mmol/mol creatinine - Adult NET patients (aged ≥ 18 years of age) - Blood and urine collection of the patient are collected within four days Patients are allowed to be included more than once. Exclusion Criteria: - A potential subject who meets any of the following criteria will be excluded from participation in this study:

Additional Information

Official title '5-HIAA in Urine Versus 5-HIAA in Plasma in Patients With a Serotonin Producing Neuroendocrine Tumor'
Principal investigator Annemiek Walenkamp, MDPhD
Description In midgut NETs serotonin production is most prominent. Patients with NETs producing excessive serotonin can develop carcinoid syndrome. Serotonin is a product of the 'tryptophan pathway'. Serotonin is metabolized in 5-hydroxyindolacetic acid (5-HIAA) and then excreted with urine. 5-HIAA in 24-hour urine collection is one of the parameters used for follow up in patients with a serotonin-producing neuroendocrine tumor. This measurement has some disadvantages; it could be stressful, the collection is not always precisely, furthermore the collection could be problematic, for example in patients with diarrhea. Since October 2013 it is possible, because of a better measurement sensitivity, to measure reliably 5-HIAA in platelet rich plasma (PRP) by isotope-dilution massa-spectrometer (LCMS-MS). Recent publications show that 5-HIAA measured in PRP could have an additive value in diagnosis and follow up of patients with serotonin-producing NET. Objective: The primary objective is to measure the correlation between 5-HIAA in PRP and 5-HIAA in 24-hours urine collection in adult patients with a serotonin-producing neuro-endocrine tumor. Secondary objective is to determine if increase or decrease of 5-HIAA in plasma is associated with disease progression. Study design: This is an observational laboratory study. Plasma and urine of included patients and collected in standard health care, are selected and the 5-HIAA's are measured with LCMS-MS. Also age, sex, diagnosis and clinical course of the patients will be collected from the medical record. Study population: In this study the investigators will use blood and urine of 60 patients with serotonin-producing neuro-endocrine tumors. Main study parameters/endpoints: The main endpoint of this study is the correlation between 5-HIAA in PRP and 5-HIAA in 24-hour urine collection. Secondary endpoint is the correlation between 5-HIAA in PRP and course of the disease, determined by CT-scan (if applicable).
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by University Medical Center Groningen.